A systematic review on multipotent carcinogenic agent, N-nitrosodiethylamine (NDEA), its major risk assessment, and

Pracheta Janmeda1, Divya Jain1, Priya Chaudhary1

  • 1Department of Bioscience and Biotechnology, Banasthali Vidyapith, Tonk, Rajasthan, India.

PubMed

Insights

N-nitrosodiethylamine (NDEA) is a probable human carcinogen causing liver and kidney damage through DNA adducts and oxidative stress. Precautions during handling are crucial to prevent NDEA-induced cancers, as treatments remain limited.

Area of Science:

  • Toxicology
  • Carcinogenesis
  • Biochemistry

Background:

  • N-nitrosodiethylamine (NDEA) is classified as a probable human carcinogen (IARC 2A) and mutagen.
  • NDEA occurs naturally, in tobacco smoke, and is synthesized endogenously.
  • Exposure can lead to severe liver and kidney damage.

Purpose of the Study:

  • To review NDEA's mechanisms of toxicity, including bioactivation and oxidative stress.
  • To discuss the role of NDEA in multi-organ carcinogenesis.
  • To highlight protective strategies and handling precautions against NDEA exposure.

Main Methods:

  • Review of existing literature on NDEA toxicity and carcinogenicity.
  • Analysis of NDEA's metabolic activation by CYP450 enzymes.
  • Examination of oxidative stress pathways and antioxidant defense mechanisms.

Main Results:

  • NDEA bioactivation by CYP450 forms DNA adducts, initiating alkylation.
  • Increased reactive oxygen species (ROS) production leads to oxidative stress and cellular damage.
  • NDEA exposure alters tissue antioxidant systems, potentially contributing to multi-organ cancer development.

Conclusions:

  • NDEA poses significant carcinogenic and mutagenic risks, necessitating careful handling.
  • Understanding NDEA's bioactivation and oxidative stress mechanisms is key to mitigating its toxicity.
  • Preventive measures and protective agents are vital for reducing the incidence of NDEA-induced cancers.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
163
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
128